

The Launching Pad: Exploring the Potential of the IL-23 Pathway in Psoriatic Arthritis

This Janssen-sponsored satellite symposium took place on 3rd June 2021, as part of the European Alliance of Associations for Rheumatology (EULAR) 2021 virtual congress

Chairperson:	Georg Schett
Presenters:	Christopher Griffiths, ¹ Georg Schett, ² Stefan Siebert ³
	<ol style="list-style-type: none">1. Dermatology Centre, University of Manchester, UK2. Universitätsklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany3. Institute of Infection, Immunity, and Inflammation, University of Glasgow, UK
Disclosure:	Griffiths has been a research supporter, principal investigator, speaker, and/or consultant for AbbVie, Ammirall, Biogen, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Sandoz, and UCB Pharma. Schett has been a research supporter and/or principal investigator for AbbVie, BMS, Eli Lilly, Janssen, Novartis, and UCB Pharma; and has participated in speakers' bureaus for AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma. Siebert has been a research supporter and/or principal investigator for Amgen, BMS, Boehringer-Ingelheim, Eli Lilly, Janssen, Novartis, and UCB Pharma; and has been a consultant and/or speaker for AbbVie, Biogen, BSR, Celgene, Janssen, and Novartis.
Acknowledgements:	Medical writing assistance was provided by Megan Breuer, Excerpta Medica, Amsterdam, the Netherlands.
Support:	The symposium and publication of this article were funded by Janssen. The views and opinions expressed are those of the speakers and not necessarily of Janssen.
Citation:	EMJ Rheumatol. 2021;8[Suppl 2]:2-7.

Summary

This Janssen-sponsored live symposium entitled "The Launching Pad: Exploring the Potential of the IL-23 Pathway in PsA" took place virtually at the European Alliance of Associations for Rheumatology (EULAR) 2021 virtual congress. The presentations focused specifically on the role of IL-23 in psoriatic arthritis (PsA), including an overview of PsA pathogenesis, updates on the latest treatments, and how insights from recent clinical trials can be applied as individualised treatments in daily clinical practice for patients with PsA.

Siebert discussed how emerging evidence underscores the role of the IL-23 and IL-17 pathways in the development of PsA and showed how data from recent Phase III clinical trials highlight the importance of IL-23 blockade in the achievement of American College of Rheumatology (ACR) scores, as well as dactylitis and enthesitis resolution, in patients with PsA.

Lessons learned from targeting the IL-23 pathway in psoriasis, as presented by Griffiths, demonstrated that recent advances in psoriasis treatment emphasise the importance of IL-23 pathway inhibition as an effective and safe therapy for patients with psoriasis. Recent clinical trials with IL-23 inhibitors have demonstrated the effectiveness of these treatments in the achievement of Psoriasis Area Severity

Index (PASI) 75, 90, or 100 responses in patients with psoriasis. The observed efficacy of this relatively new class of biologics also indicates that the achievement of PASI 90 or higher, instead of PASI 75, might represent the new 'gold standard' in psoriasis management.

Schett explained the importance of the IL-23 pathway in PsA management. He described how IL-23 is an upstream regulator of pro-inflammatory T-cell activation and is capable of inducing several types of pathogenic immune cells, such as T helper (Th) 17, $T\gamma\delta$, mucosal-associated invariant T cells (MAIT), and innate lymphoid cell (ILC) 3. He discussed how therapeutic inhibition of IL-12/23 with ustekinumab has been shown to lead to resolution of sub-clinical enthesitis in patients with psoriasis and in improved enthesitis control in patients with established enthesitis. He concluded by illustrating how IL-23 inhibition can also result in the resolution of dactylitis and enthesitis in patients with PsA.

In it for the Long Haul: IL-23 Pathway Inhibition in Psoriatic Arthritis

Stefan Siebert

Siebert began the symposium by illustrating how emerging evidence underscores the role of the IL-23 and IL-17 pathways in the development of PsA, and how activation of IL-23 and IL-17 can stimulate osteoproliferation, inflammation, and bone loss, and ultimately result in ankylosis of the spine in patients with PsA.¹ However, recent studies have shown that blockade of the IL-23p19 and p40 subunits can cause a differential reduction in IL-17A and IL-17F effector cytokine levels, and that blockade of the p19 subunit in particular resulted in significant improvements in joint outcomes in patients with PsA during a 52-week treatment period.^{2,3} Furthermore, treatment with the IL-23 inhibitors guselkumab, risankizumab, and tildrakizumab have resulted in improved ACR20 responses at Week 24 in patients with PsA in Phase II clinical trials.⁴⁻⁶

The DISCOVER-1 and DISCOVER-2 Phase III clinical trials examined the efficacy of guselkumab 100 mg given every 4 weeks (q4w) and 100 mg given every 8 weeks (q8w), compared with placebo.^{7,8} The DISCOVER-1 trial included 381 patients with PsA, of which 31% were previously exposed to anti-TNF therapy;⁷ the DISCOVER-2 trial included 739 biologic-naïve patients with PsA.⁸ The primary end-point of both trials was the achievement of an ACR20 response at Week 24 of treatment.^{7,8} In both trials, treatment with either guselkumab dose resulted in significant improvements compared to placebo (PBO) at Week 4 ($p < 0.05$), an effect that

continued through Week 24 of treatment ($p < 0.0001$ compared to placebo for all guselkumab-treated groups).^{7,8}

In the DISCOVER-1 trial, ACR20 responses were maintained through Week 52 of treatment in 73% and 60% of patients with guselkumab q4w (GUS q4w) and q8w (GUS q8w), respectively; in patients who switched from PBO to guselkumab 100 mg q8w at Week 24 (PBO to GUS), ACR20 response was achieved in 56% of patients at Week 52.^{7,9} Furthermore, this trial demonstrated that significant proportions of patients achieved PASI 75, 90, and 100 responses at Week 24 and through Week 52 of treatment with either guselkumab dose, as well as in patients who crossed over from placebo to guselkumab.^{7,9}

The results of the DISCOVER-2 trial revealed that 68.3% (PBO to GUS), 73.8% (GUS q8w), and 75.9% (GUS q4w) of patients achieved ACR20 responses at Week 100 of treatment.¹⁰ Furthermore, assessments of more stringent ACR criteria showed that 47.6% (PBO to GUS), 54.8% (GUS q4w), and 55.9% (GUS q8w) of patients achieved ACR50 responses, and 29.7% (PBO to GUS), 34.7% (GUS q4w), and 35.5% (GUS q8w) of patients achieved ACR70 responses at Week 100 of treatment.¹⁰ Patients receiving either a dose of guselkumab, or those who crossed over from the placebo group to guselkumab, also showed significant improvements in minimal disease activity and skin responses at Weeks 24 (GUS q4w: 19%; GUS q8w: 25%; PBO to GUS: 6%), 52 (GUS q4w: 34%; GUS q8w: 31%; PBO to GUS: 30%), and 100 (GUS q4w: 38%; GUS q8w: 40%; PBO to GUS: 37%) of treatment.¹⁰ Promising results indicate that treatment with guselkumab 100 mg q4w or q8w also has a significant impact on dactylitis and enthesitis resolution, as well as improvements in patient quality of life, at Weeks 24, 52, and 100 of treatment (data on file).

Pooled data from both the DISCOVER-1 and DISCOVER-2 trials also indicated that long-term treatment with guselkumab did not result in any new safety signals, further underscoring the long-term efficacy and safety of IL-23p19 inhibition in patients with PsA.¹⁰

Lessons Learned from Targeting the IL-23 Pathway in Psoriasis

Christopher Griffiths

Griffiths shared the dermatological perspective on the latest information regarding lessons learned from targeting the IL-23 pathway, noting that approximately 30% of patients with psoriasis will develop PsA and 30% will suffer from concomitant depression or anxiety.¹¹ He also described the importance of IL-17 and IL-23 in the pathogenic inflammatory loop in psoriasis pathogenesis, noting how environmental and genetic triggers can stimulate the production of inflammatory cytokines by keratinocytes, which then produce cytokines that activate dendritic cells to produce IL-23. This drives the production of Th17 cells, which then activates a cascade of cytokines to drive the activation of macrophages, mast cells, neutrophils, and other innate lymphoid cells, ultimately resulting in a pro-inflammatory immune response loop.¹²

Recent advances in psoriasis treatment have highlighted the importance of IL-23 pathway inhibition, which shows good efficacy and a favourable safety profile for patients with psoriasis. For example, a recent study showed that patients with psoriasis who were treated with the IL-23 inhibitor guselkumab showed greater PASI 90 responses at Week 48 of treatment, compared with patients who received the IL-17A inhibitor secukinumab (84% versus 70%, respectively; $p < 0.0001$).¹³ Similarly, in a study with the IL-23 inhibitor risankizumab, a higher proportion of patients achieved PASI 90 at Week 52, compared with patients who received secukinumab (87% versus 57%, respectively; $p < 0.001$).¹⁴ There are differences, however, even between inhibitors in the IL-17A class, and the IL-17 inhibitor ixekizumab demonstrated similar efficacy for skin clearance at Week 24 of treatment compared with guselkumab in the IXORA-R study (50% versus 52%, respectively).¹⁵

The observed high efficacy of current biologic therapies indicates that the achievement of PASI 90 or higher, instead of PASI 75, might represent the new 'gold standard' in psoriasis management. For example, evidence from the VOYAGE 1 study indicated that 83.1% (treatment failure rules; TFR) of patients treated with guselkumab achieved PASI 90 responses through Week 252 of continuous treatment. Furthermore, 51% (TFR) of patients receiving guselkumab achieved and maintained PASI 100 at the same time-point.¹⁶ The VOYAGE 1 study also showed that patients achieved and maintained Dermatology Life Quality Index (DLQI) scores of 0 or 1 from Week 76 through Week 252 of treatment with guselkumab.¹⁷ Further evidence of the sustainable effect of IL-23 inhibition on skin clearance comes from the reSURFACE 1 and 2 studies with tildrakizumab and LIMMitless study with risankizumab, which also demonstrated that patients treated with these IL-23 inhibitors showed sustained PASI responses through Week 244 and Week 196 of treatment, respectively.^{18,19}

Safety analyses of IL-23 inhibitors generally showed no new safety signals: pooled data from the VOYAGE 1 and 2 trials demonstrated that adverse event rates were low and remained stable over time through 5 years of treatment with guselkumab.²⁰ Similarly, the results of the LIMMitless and reSURFACE 1 and 2 trials showed low rates of adverse events in patients treated with risankizumab through Week 224 of treatment and with tildrakizumab through Week 252 of treatment, respectively.^{18,19}

Finally, there is the hope that newer treatments could lead to long-term remission. The underlying mechanism includes T cells infiltrating the epidermis during active disease, becoming tissue-resident memory T cells, and establishing a site-specific disease memory that can potentially result in lesion recurrence.²¹ Studies have shown that therapeutic blockade of IL-23p19, but not IL-17A, reduced the frequencies of CD8⁺ tissue-resident memory T cells in resolved plaques, indicating that treatment with IL-23 inhibitors may also offer patients long-term skin clearance benefits, even after cessation of treatment.²²

Why IL-23? Psoriatic Arthritis Pathophysiology Through the Domains

Georg Schett

Schett began his presentation by illustrating the domain-specific cytokine responses in the eye, spine, gut, and skin of patients with PsA.²³ He discussed the important role that IL-23 plays in these domains, noting that IL-23 inhibition effectively reduces T-cell infiltration in psoriatic plaques.²⁴ IL-23 can also expand pathogenic T cell numbers in patients with Crohn's disease, as IL-23 derived from macrophages can lead to the expansion of apoptosis-resistant IL-23-positive T cells.²⁵

IL-23 is an upstream regulator of proinflammatory T cell activation, and can induce several types of pathogenic immune cells, such as Th17, $\gamma\delta$, MAIT, and ILC3. Th17 cells have been found to circulate in higher numbers in the blood of patients with psoriasis and PsA.²⁶ $\gamma\delta$ cells are increased in the synovial fluid of patients with PsA, and can also be found in inflamed entheses.²⁷ MAIT cells are derived from the gut and can move to the joints of patients with PsA, further underscoring the communication between the gut and the joints in PsA pathogenesis.²⁸ Finally, ILC3 cells are enhanced in the circulation of patients with active PsA and correlate with joint damage; these cells are also associated with disease activity in patients with PsA.²⁹

IL-23 triggers enthesal inflammation by activating T cells and downstream effector cytokines. Overexpression of IL-23 can lead to psoriasis-like inflammation of the skin, as well as the development of enthesitis, characterised by infiltration of the joint with neutrophils, T cells, and macrophages.^{30,31} In pre-clinical studies, IL-23 activation also led to the accumulation of $\gamma\delta$ cells in the entheses, resulting in enthesitis and new bone formation.³² Furthermore, a recent study revealed that the appearance of enthesal lesions is an important predictor of the transition from psoriatic skin disease to joint disease.³³ Therapeutic inhibition of IL-12/23 with ustekinumab, however, has been shown to lead to resolution of sub-clinical enthesitis in patients with psoriasis,³⁴ and to improved enthesitis control compared to anti-TNF therapy in patients

with established enthesitis.³⁵ IL-23 inhibition also resulted in the resolution of dactylitis and enthesitis after 24 weeks of treatment in patients with PsA.^{36,37}

Panel Discussion

The faculty responded to a variety of questions during the panel discussion moderated by Siebert. The first question focused on why many patients with psoriasis who achieve clearance (PASI 100) of their skin symptoms do not necessarily also achieve DLQI 0/1. Griffiths replied that patients who achieved PASI 100 are often anxious about how durable the effect might be, based on previous experience with only short-lived clearance. Additionally, even with clearance of skin symptoms, patients may still suffer from PsA.

The next question was whether a very good response in the skin might also be predictive of a good response in the joints. Griffiths and his colleagues agreed that the earlier a patient receives treatment, the more likely clearance of skin symptoms and one of the underlying mechanisms may be that early treatment could prevent a tissue-resident memory from being established. However, Schett pointed out that, for the most part, patients with PsA are treated late, several years into the course of their disease. This may also explain why only a minority of patients with PsA see a substantial improvement beyond ACR20. Furthermore, as psoriasis usually precedes the onset of PsA symptoms, it may be possible that by treating skin symptoms early and with highly efficacious medications, the later occurrence of PsA could be prevented. It will be interesting to identify biomarkers that could predict which patients will later develop PsA. This would be a big step towards next-generation healthcare.

The viewers were also interested in understanding whether drug withdrawal could be considered for patients with PsA. Siebert cautioned that drug withdrawal may be difficult in patients with an established disease, while Schett argued that genetic factors are very important in psoriatic disease. Additionally, mechanical stimuli and metabolic factors also need to be taken into consideration as underlying triggers of the disease. Obesity in particular is a driver of

PsA and by controlling and reducing weight, PsA symptoms can be improved.

In conclusion, the speakers summarised that in order to achieve long-term control of both PsA and psoriasis, it is important to address factors relating to the patient's lifestyle (namely

establishing a regular exercise regimen, achieving weight loss, and stopping smoking); treat patients with the right drug, preferably with highly efficacious medications such as IL-23 inhibitors; and to do so at an early stage of the disease.

References

1. Ghoreschi K et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. *Lancet*. 2021;397(10275):754-66.
2. Siebert S et al. OPO229 Guselkumab induces sustained reduction in acute phase proteins and Th17 effector cytokines in active psoriatic arthritis in two Phase-3 clinical trials (DISCOVER-1 and DISCOVER-2). *Ann Rheum Dis*. 2020;79(Suppl 1):144-5.
3. Diels J et al. AB0556 Comparing efficacy of guselkumab versus ustekinumab in patients with psoriasis arthritis: an adjusted comparison using individual patient data from DISCOVER-1&2 and PSUMMIT trials. *Ann Rheum Dis*. 2021;80(Suppl 1):1313.
4. Deodhar A et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. *Lancet*. 2018;391(10136):2213-24.
5. Mease PJ et al. OPO307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. *Ann Rheum Dis*. 2018;77(Suppl 2):200-1.
6. Mease PJ et al. LB0003 Randomised, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis. *Ann Rheum Dis*. 2019;78(Suppl 2):78-9.
7. Deodhar A et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNF α inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020;395(10230):1115-25.
8. Mease PJ et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020;395(10230):1126-36.
9. Ritchlin CT et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNF α inhibitor-experienced. *RMD Open*. 2021;7(1):e001457.
10. McInnes I et al. POS1027 Efficacy and safety of guselkumab, a monoclonal antibody specific to the p19-subunit of interleukin-23, through 2 years: results from a Phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. *Ann Rheum Dis*. 2021;80(Suppl 1):783-4.
11. Koo J et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. *J Eur Acad Dermatol Venereol*. 2017;31(12):1999-2009.
12. Griffiths CEM et al. Psoriasis. *Lancet*. 2021;397(10281):1301-15.
13. Reich K et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. *Lancet*. 2019;394(10201):831-9.
14. Warren RB et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. *Br J Dermatol*. 2021;184(1):50-9.
15. Blauvelt A et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. *Br J Dermatol*. 2021;184(6):1047-58.
16. Griffiths CEM et al. Maintenance of response through 5 years of continuous guselkumab treatment: results from the phase 3 VOYAGE 1 trial. 2019 Fall Clinical Dermatology Conference. 17-20th October 2019.
17. Griffiths CEM et al. Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1. Poster P27043. American Academy of Dermatology Virtual Meeting Experience (AAD VMX) conference, 23-25 April 2021.
18. Thaçi D et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomised phase 3 clinical trials (reSURFACE1 and reSURFACE 2) through 5 years. Abstract D3T03.3C. Late breaking abstract presented at the EADV Congress, 29-31 October 2020
19. Papp K et al. Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: an interim analysis of the LIMMitless open-label extension trial. Poster 26186. Presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) conference, 23-25 April 2021.
20. Blauvelt A et al. Long-term safety of guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment. Poster P28095. American Academy of Dermatology Virtual Meeting Experience (AAD VMX) conference, 23-25 April 2021.
21. Cheuk S et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. *J Immunol*. 2014;192(7):3111-20.
22. Gordon KB et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 Study. *J Invest Dermatol*. 2019;139(12):2437-46.e1.
23. Maksymowych WP et al. MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation. *Arthritis Res Ther*. 2017;19(1):126.
24. Kopp T et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. *Nature*. 2015;521(7551):222-6.
25. Schmitt H et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. *Gut*. 2019;68(2):814-28.
26. Benham H et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. *Arthritis Res Ther*. 2013;15(5):R136.

27. Guggino G et al. Interleukin (IL)-9/IL-9R axis drives $\gamma\delta$ T cells activation in psoriatic arthritis patients. *Clin Exp Immunol*. 2016;186(3):277-83.
28. Raychaudhuri SK et al. Functional significance of MAIT cells in psoriatic arthritis. *Cytokine*. 2020;125:154855.
29. Soare A et al. Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. *J Immunol*. 2018;200(4):1249-54.
30. Schett G et al. Enthesitis: from pathophysiology to treatment. *Nat Rev Rheumatol*. 2017;13(3):731-41.
31. Sherlock JP et al. IL-23 induces spondyloarthropathy by acting on ROR- γ t+ CD3+CD4-CD8- enthesial resident T cells. *Nat Med*. 2012;18(7):1069-76.
32. Reinhardt A et al. Interleukin-23-dependent $\gamma\delta$ T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. *Arthritis Rheumatol*. 2016;68(10):2476-86.
33. Simon D et al. Micro-structural bone changes are associated with broad-spectrum autoimmunity and predict the onset of rheumatoid arthritis. *Arthritis Rheumatol* 2020;DOI:10.1002/art.41229.
34. Savage L et al. Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. *Arthritis Rheumatol*. 2019;71(4):626-31.
35. Araujo EG et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. *Semin Arthritis Rheum*. 2019;48(4):632-7.
36. McGonagle D et al. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two Phase-3 psoriatic arthritis studies. *Rheumatology (Oxford)*. 2021;DOI:10.1093/rheumatology/keab285.
37. McInnes IB et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. *Arthritis Rheumatol*. 2021;73(4):604-16.

Date of preparation: June 2021
CP-242157